Skip to content
2000
  • ISSN: 1568-0053
  • E-ISSN: 1875-5852

Abstract

The multistep nature of HIV-1 entry provides multisite targeting at the entrance door of HIV-1 to cells. Blocking HIV-1 entry to its host cells has clear advantages over blocking subsequent stages in the life cycle of the virus. Indeed, potent cooperative and synergistic inhibition of HIV-1 proliferation has been observed in in vitro studies with several entry inhibitor combinations, interacting with different steps of the HIV-1-cell entry cascade. Targeting a compound to several steps of the viral-cell entry and also to subsequent steps in the viral life cycle promises an even more effective therapeutic, by reducing the probability of HIV-1 to develop resistance. Using one drug that can target multiple sites and / or steps in the viral life cycle will have obvious advantages in clinical use. In this article we review the multistep process of HIV-1 cell entry and the current repertoire of inhibitors of this critical stage in the viral life cycle, and introduce an example of multisite HIV-1 targeting of the cell entry and subsequent critical steps in the viral life cycle.

Loading

Article metrics loading...

/content/journals/cdtid/10.2174/1568005053174645
2005-03-01
2025-09-28
Loading full text...

Full text loading...

/content/journals/cdtid/10.2174/1568005053174645
Loading

  • Article Type:
    Review Article
Keyword(s): aacs; ccr5; cxcr4; entry inhibitors; gp120; gp41; hiv-1; membrane fusion
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test